Rhythm Biosciences Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	1.7yrs
Promedio de permanencia en la Junta Directiva	5.8yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Rhythm Biosciences no tiene CEO, o no tenemos datos al respecto.

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Otto Buttula	Executive Chairman	4.7yrs	AU$373.84k	14.06% A$ 2.5m
Guy Carisbrooke	Financial Controller	less than a year	sin datos	sin datos
Andrea Steele	General Counsel & Joint Company Secretary	2.3yrs	sin datos	sin datos
Elena Deak	Chief Commercial Officer	1.7yrs	sin datos	sin datos
James Barrie	Joint Company Secretary	less than a year	sin datos	sin datos

1.7yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de RHY no se considera experimentado ( 1.5 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Otto Buttula	Executive Chairman	4.7yrs	AU$373.84k	14.06% A$ 2.5m
Louis Panaccio	Non-Executive Director	6.8yrs	AU$66.86k	0.43% A$ 75.5k
Susan MacLeman	Independent Deputy Chair	1.4yrs	AU$21.88k	sin datos
Trevor Lockett	Non-Executive Director	7yrs	AU$207.38k	0.66% A$ 117.5k

5.8yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: La junta directiva de RHY se considera experimentada (5.6 años de antigüedad promedio).

Rhythm Biosciences Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Rhythm Biosciences Limited Announces Resignation of Rachel David as Non-Executive Director

Rhythm Biosciences Ltd Announces the Appointment of James Barrie as Joint Company Secretary, Effective 1 January 2024

Rhythm Biosciences Limited, Annual General Meeting, Oct 10, 2023

Executive Chairman recently bought AU$248k worth of stock

Rhythm Biosciences Ltd Appoints Sue MacLeman as an Independent, Non-Executive Director

Eduardo Vom Retires as A Non-Executive Director of Rhythm Biosciences Limited

Recent updates

New major risk - Shareholder dilution

Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 2.483947 million.

Rhythm Biosciences Limited has filed a Follow-on Equity Offering in the amount of AUD 6.634278 million.

Rhythm Biosciences Limited Announces Resignation of Rachel David as Non-Executive Director

Rhythm Biosciences Ltd Announces the Appointment of James Barrie as Joint Company Secretary, Effective 1 January 2024

New minor risk - Share price stability

New minor risk - Shareholder dilution

Rhythm Biosciences Limited, Annual General Meeting, Oct 10, 2023

New major risk - Financial position

New minor risk - Financial data availability

Executive Chairman recently bought AU$248k worth of stock

Rhythm Biosciences Ltd Appoints Sue MacLeman as an Independent, Non-Executive Director

Eduardo Vom Retires as A Non-Executive Director of Rhythm Biosciences Limited

Less than half of directors are independent

Rhythm Biosciences Limited, Annual General Meeting, Nov 29, 2022

Rhythm Biosciences Limited Appoints Paul Smith as Chief Financial Officer

Executive Chairman recently sold AU$6.5m worth of stock

Full year 2022 earnings released: AU$0.042 loss per share (vs AU$0.036 loss in FY 2021)

Rhythm Biosciences Limited Advances Platform Expansion with Other Cancers

Less than half of directors are independent

Rhythm Biosciences Announces the Statistical Analysis Outcomes of Its Clinical Trial (Study 7) as Verified by Rhythm's Third-Party Statisticians for ColoSTAT ®

Rhythm Biosciences Ltd Announces Executive Changes

Rhythm Biosciences Limited announced that it expects to receive AUD 6.532651 million in funding

Rhythm Biosciences Limited Completes Recruitment for Clinical Trial (Study 7)

Non-Executive Director David White has left the company

Rhythm Biosciences Adds Sonic Clinical Services to Colostat Clinical Trial

Rhythm Biosciences Betters ColoSTAT Results

New 90-day high: AU$1.64

Rhythm Biosciences Limited Expands ColoSTAT Clinical Trial to Tenth Site

New 90-day high: AU$1.58

Rhythm Advances ColoSTAT® Study 7, adding 2 New Clinical Trial sites

New 90-day high: AU$1.37

New 90-day high: AU$0.88

Rhythm Biosciences Limited Appoints Biotem Limited as the Global Manufacturer of its ColoSTAT® Test-Kit

New 90-day high: AU$0.26

New 90-day high: AU$0.22

Rhythm Biosciences Limited Announces Rhythm Biosciences Limited Joins the ColoSTAT® Clinical Trial

Rhythm Biosciences Limited has completed a Follow-on Equity Offering in the amount of AUD 3.627 million.

Rhythm Biosciences Limited announced that it expects to receive AUD 2.40675 million in funding

CEO

Equipo directivo

Permanencia media

Miembros de la Junta

Permanencia media

Promedio de edad